Term/phenotype[1] | Previous nomenclature[2] | Definitions |
Steatotic liver disease | Fatty liver disease |
|
Metabolic dysfunction-associated steatotic liver disease (MASLD) | Nonalcoholic fatty liver disease (NAFLD) |
|
Metabolic dysfunction-associated steatohepatitis (MASH) | Nonalcoholic steatohepatitis (NASH) |
|
Definite MASH |
| |
Borderline MASH, zone 3 pattern | Type 1 |
|
Borderline MASH, zone 1 pattern | Type 2 |
|
MASLD with fibrosis or cirrhosis | NAFLD with fibrosis or cirrhosis |
|
MASLD and increased alcohol intake (MetALD) | None (new category) |
|
A1C: glycated hemoglobin; BMI: body mass index; BP: blood pressure; HDL: high-density lipoprotein; MASH: metabolic dysfunction-associated steatohepatitis; MASLD: metabolic dysfunction-associated steatotic liver disease; MetALD: MASLD and increased alcohol intake; NAFLD: nonalcoholic fatty liver disease; NASH: nonalcoholic steatohepatitis.
* Pediatric criteria for cardiometabolic risk factors are[1]:¶ UpToDate suggests using BP ≥130/80 as a cardiometabolic risk factor for children ≥13 years; this is the threshold for defining hypertension in this age group, as defined by the American Heart Association[3]. Rinella[2] used BP ≥130/85, which is the threshold for defining metabolic syndrome in adolescents that was proposed by the International Diabetes Federation in 2007 but has not been reevaluated since then.
Do you want to add Medilib to your home screen?